## 1 Introduction
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Pharmacologic Active** & **Formulation** & **Route of Administration** & **Indication and Frequency** \\
**Ingredi** & & & Treatment of postmenopausal osteoporosis (\(\overline{V}\) mfg/week) \\
**A**hendronic acid (sodium sal0) & Tab 10 mg & FO & Treatment of osteoporosis in men (\(\overline{V}\)) mfg/week) \\  & & & Treatment and prevention of osteoporosis induced by glucocorticoids (\(\overline{V}\) mfg/week) \\ \hline Alendronic acid + & Tab 70 mg/5600 U1 & FO & Treatment of postmenopausal osteoporosis in patients with unssupplemented Vitamin D deficit (\(\overline{V}\) mfg/week) \\ chochalcogenides & Tab 80 mg & FO & Prevention of SRFs in breast cancer patients with bone metastases (\(\overline{V}\) mfg/day p.o. or \(\overline{V}\) 6 mg every 3-4 weeks iv.) \\ \hline Ibandronic acid (monosodium salt monohydrate) & Tab 150 mg & FO & Treatment of postmenopausal osteoporosis in patients at high risk of fracture (\(\overline{V}\) 150 mg/4 weeks p.o. or \(\overline{V}\) 3 mg \\  & & & Fever 3 months is) \\ \hline Neridronate acid (sodium sal0) & Bl 25 mg/2 mL & IV/IM & Osteogenesis imperfects (2 mg/kg/3 months) \\  & Bl 100 mg/s mL & IV & Treatment of [PERSON]’s disease (different schedules) \\ \hline \multirow{2}{*}{Risedronic acid} & Tab 35 mg & \multirow{2}{*}{PO} & Treatment of postmenopausal osteoporosis (\(\overline{V}\) mfg/week) \\  & Tab 5 mg & & Treatment and prevention of osteoporosis induced by glucocorticoids (\(\overline{V}\) 25 mg weekly or 5 mg daily) \\  & Tab 5 mg & & Treatment of [PERSON]’s disease \\ \hline \multirow{2}{*}{Zoledronic acid (monohydrate)} & \multirow{2}{*}{Bl 4 mg/5 mL} & \multirow{2}{*}{IV} & Prevention of SRFs in cancer patients with bone metastases or MM (4 mg every 3-4 weeks). Treatment of hypercalcemia of malignancy \\  & & & Treatment of osteoporosis in postmenopausal women, in men at increased risk of fracture, including those with a record by fracture from minor trauma (5 mg one per year) \\  & & & Treatment of [PERSON]’s disease \\ \hline \multirow{2}{*}{Densouramb} & Bl 120 mg & SC & Prevention of SRFs in cancer patients with bone metastases (120 mg every 4 weeks) \\  & Bl 60 mg & SC & Treatment of hyperalcemia of malignancy. \\  & & & Osteoporosis (\(\overline{V}\) 60 mg sc. every 6 months) \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Antiresorptive drugs associated with medication-related osteeoncrosis of the jaws (MRONJ). Blt: Bottle; IM: Intramuscular; IV: Intravenous; MM: Multiple myeloma; PO: Orally; SC: Subcutaneous; SRE: Skeletal-related event; Tab: Tablet. _Appl. Sci._**2019**, \(9\), 1026 \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Pharmacologic** & **Formulation** & **Route of** & \\
**Active Ingredient** & **Formulation** & **Administration** & **Indication and Frequency** \\ \hline  & & & Metastatic breast cancer (10 mg/kg every \\  & & & 2 weeks or 15 mg/kg every 3 weeks); \\  & & & colorectal cancer (5 mg/kg or 10 mg/kg \\ Bevacizumabab & Blt 400 mg & IV & every 2 weeks); lung/ovarian cancer \\  & & & (7.5 mg/kg or 15 mg/kg every 3 weeks); \\  & & & renal cell cancer (10 mg/kg every 2 weeks); \\  & & & glioblastoma (10 mg/kg every 2 weeks) \\ \hline  & & & Renal cell cancer, GISTs and \\ Sunitinib & Tab 12.5 mg & PO & neuroendocrine tumours (50 mg/day for \\  & & & 4 weeks) \\ \hline Sorafenib & Tab 200 mg & PO & Renal cell cancer (800 mg/day) \\ \hline Pazopanib & Tab 200 mg & PO & Renal cell cancer (200–800 mg/day) \\ \hline Thalidomide & Tab 50 mg & PO & Myeloma (400 mg/day for 6 weeks) \\ \hline Lenalidomide & Tab 5, 10, 15 and 25 mg & PO & Myeloma (tailored doses) \\ \hline Everolimus & Tab 5 and 10 mg & PO & Renal cell cancer, breast cancer (10 mg \\  & & & every day) \\ \hline Temsirolimus & Blt 30 mg & IV & Renal cell cancer (25 mg every week) \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Antiangiogenic drugs associated with MRONJ. IV: Intravenous; MM: Multiple myeloma; PO: Orally; SC: Subcutaneous; Btl: Bottle; Tab: Tablet.